eli lilly retatrutide press release 2024 2025 is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Lilly orforglipron oral GLP-1 phase

Patients who are already managing the once-weekly injection cadence of Semaglutide or Tirzepatide and do not want to add daily injections are not good candidates for GHK-Cu, not because of any contraindication, but because they wont maintain the protocol consistently enough to see results

Sherwin et al., 2011

doi: 10.2337/diabetes.54.suppl_2.s108

Higher doses amplify GLP-1 receptor activity in areas of the brain, like the Area Postrema, which is responsible for triggering nausea

A lightweight, essence-like toner that delivers deep hydration while visibly improving skin texture and tone

Small amounts of L-carnitine have been given to infants in their breast milk and the formula with no reported side effects